We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cello Health Plc | LSE:CLL | London | Ordinary Share | GB00B0310763 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 161.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/7/2019 19:20 | nice uptick today. A guarded upgrade IMO, yet market hasn't really digested it....more to come, maybe increase in divi? DYOR | qs99 | |
18/7/2019 12:02 | Yes, that is possible, QS. A win either way, atm. | poikka | |
18/7/2019 10:26 | if that is an average of the peer group, how long before someone takes "a look" at CLL? or management get bored with the share price and do something about it?! DYOR | qs99 | |
18/7/2019 10:22 | Picked some of these up first thing. The stock has fallen from recent highs just under 140 for no reason. Trading is strong and warrants a move back up on unjustified market jitters. "At least in line", which basically means they're ahead and forecasts will be upgraded. FinnCap are also alluding to this, but have not changed forecasts yet. Stock is up 7% at present as Mr Market isn't waiting about for that upgrade, price it in ahead. Here's FinnCap: "Cello’s Health division has had an “excellentR "Valued at a discount to peers.The potential for above average long-term growth(both organically and by acquisitions which Cello continues to assess)in a defensive market means the peer group is highlyrated at an average P/E of 24.7x in FY 2019, including UK quoted peer UDG at 21x. Cello isvalued at a FY 2019 P/E of 13.2x" This will get tasty if it can breakthrough 140 in the future. Let's see how we get on. | sphere25 | |
18/7/2019 09:29 | Yes, the outlook was more upbeat than the finals | zipstuck | |
18/7/2019 08:41 | Good update, and nothing to add other than nice to see a ray of sunshine in the global gloom. | poikka | |
02/7/2019 12:45 | They sold 600,000 out of 950,000 options vested. A bit more than covering their tax! | coopstock | |
02/7/2019 11:47 | Good point zipstuck | barnesian | |
02/7/2019 11:22 | I think the share option message is that when they sell part of the options they are selling to cover the tax and NI costs. In effect they are adding so I'm happy to hold | zipstuck | |
28/6/2019 13:53 | Poor response - filtered. | poikka | |
28/6/2019 10:34 | It's happened three years running and it'll happen again next time - but of course you boys know best... | coopstock | |
28/6/2019 10:26 | Well yes, it doesn't help, but I doubt that it added any pressure to the share price At least they only flogged just over half of those shares, except for the FD, wasn't it. Still, agree with your comments. Yesterday's fall was quite dramatic, and hopefully due to a rubbish trade. Maybe more small company OIECs trying to avoid Woody's woes. Best to avoid small company ITs for a while, I guess, having only recently bought some EWI and JMI.. | poikka | |
28/6/2019 08:20 | Badly executed sell? Buying opportunity? | poikka | |
27/6/2019 18:55 | No, I can't see that Woddford PC holds any, or didn't at the Finals. | poikka | |
27/6/2019 18:49 | WTF! Woodford flogging some? Anyone got any news? Coopstock, what do you mean "more dilution"? | poikka | |
25/6/2019 09:10 | More dilution and more pressure on the share price just when we don’t need it | coopstock | |
15/5/2019 08:16 | Kabouter? Never heard of them, but nice to see that they like us :) | poikka | |
21/3/2019 21:34 | That is true (Cenkos), but that growth is taking a long time to come. But then I've held them for 9 years. | poikka | |
21/3/2019 10:44 | Cenkos; Organic momentum continues Today’s largely in-line results were well flagged by January’s trading update, but there are notable beats on EPS, DPS and Net cash. The group continues its organically focused delivery, leveraging Signal’s digital capabilities into the healthcare space, alongside new office openings. This will continue Cello’s migration over time into a more healthcare-focused, US-centric and higher margin business. We feel the defensive nature and FCF potential of Cello are not fairly valued in the current share price. | davebowler | |
21/3/2019 08:06 | Ok, not startling. Growth hard to come by. Think I'll hold. | poikka | |
04/2/2019 15:20 | Cello Health will be presenting to investors at the upcoming Proactive One2One Forum on Thursday 7th F Details and registration: | aim_trader | |
23/1/2019 14:14 | I guess the weakness is due to the slower Signal and charge this year for closing Cheltenham. | zipstuck | |
21/1/2019 09:20 | Reasonable divi with some growth to come | zipstuck | |
17/1/2019 08:44 | Nice enough update - cash & Health good, Signal not so, and expectations in line. Makes up for gloom elsewhere. | poikka |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions